1. Home
  2. CEVA vs PRTC Comparison

CEVA vs PRTC Comparison

Compare CEVA & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CEVA Inc.

CEVA

CEVA Inc.

HOLD

Current Price

$21.83

Market Cap

642.7M

Sector

Technology

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

HOLD

Current Price

$16.91

Market Cap

386.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CEVA
PRTC
Founded
1999
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
642.7M
386.7M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
CEVA
PRTC
Price
$21.83
$16.91
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$34.20
N/A
AVG Volume (30 Days)
828.8K
4.8K
Earning Date
11-10-2025
08-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.20
Revenue
$107,530,000.00
$6,391,000.00
Revenue This Year
$4.41
N/A
Revenue Next Year
$14.26
N/A
P/E Ratio
N/A
$7.77
Revenue Growth
5.55
1265.60
52 Week Low
$18.23
$13.30
52 Week High
$38.94
$23.35

Technical Indicators

Market Signals
Indicator
CEVA
PRTC
Relative Strength Index (RSI) 44.01 51.09
Support Level $21.56 $16.44
Resistance Level $23.56 $17.17
Average True Range (ATR) 0.98 0.35
MACD 0.37 0.12
Stochastic Oscillator 61.43 55.29

Price Performance

Historical Comparison
CEVA
PRTC

About CEVA CEVA Inc.

CEVA Inc is a licensor of signal-processing intellectual property. Through partnerships with semiconductor companies and original equipment manufacturers globally, the company helps produce devices for a range of end markets. OEMs and semiconductor companies choose to sell products with CEVA equipment to wireless, consumer, automotive, and Internet of Things companies. Revenue is derived primarily from licensing fees and related revenue, and royalties generated from the shipments of products utilizing its intellectual properties. CEVA also engages in the training and sale of development systems.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: